Related Experiment Video
Updated: Jun 10, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Comparison of Robotic and Laparoscopic Approaches for Para-Aortic Lymphadenectomy in Patients With Endometrial or
Tomoyuki Sasano1, Rose Taniguchi1, Yumi Takimoto1
1Department of Obstetrics and Gynecology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Aim:
To compare the surgical and oncological outcomes between robotic and laparoscopic para-aortic lymphadenectomy (PALND) in Japanese women with endometrial cancer or ovarian cancer.
Methods:
This retrospective study included patients who underwent minimally invasive surgery, including PALND, between March 2018 and January 2025 at three Japanese institutions. Patients with endometrial cancer or ovarian cancer were divided into robotic and laparoscopic surgery groups. Surgical outcomes and oncological outcomes were compared between the two groups.
Results:
A total of 60 patients were analyzed (robotic group: n = 33; laparoscopic group: n = 27). The operative time was significantly longer in the robotic group, whereas intraoperative blood loss did not differ significantly between the groups. No significant differences were observed in intraoperative or postoperative complication rates, nor in the length of hospital stay. The total number of retrieved pelvic and para-aortic lymph nodes was comparable between the two groups [70.0 (robotic group) vs. 72.5 (laparoscopic group), p = 0.480]. Furthermore, there were no significant differences in overall survival (p = 0.483) or progression-free survival (p = 0.837) between the groups.
Conclusions:
Robotic PALND demonstrated perioperative safety, surgical quality, and oncological outcomes comparable to those of laparoscopic PALND. These findings suggest that robotic-assisted PALND can be performed safely and effectively, with outcomes comparable to those achieved with conventional laparoscopic approaches in Japanese patients with gynecological cancers.
